Domatinostat

PreclinicalSmall molecule

RRoyal Marsden NHS Foundation Trust

Domatinostat is one of 16 small molecule programs targeting Sarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SarcomaRecruiting

SarcomaPreclinical

Recruiting

Competition

Competitive Landscape

18 competitors in Sarcoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

2 2

Keytruda

Merck & Co.

Phase 2

2 3

Tecentriq

Roche

Phase 2

1 4

Amtagvi

IIovance Biotherapeutics, Inc.

Phase 2

1 5

IC-Green

PProvepharm SAS

Phase 2

1 6

Talimogene Laherparepvec

Amgen

Phase 2

3 7

Biological

NNational Environment Agency, Singapore

Phase 1

1 8

NKTR-214

Bristol-Myers Squibb

Phase 2

1 9

Rapamune

PPrism Pharmaceuticals

Preclinical

1 10

NEULASTA

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

PreclinicalRecruiting

Sarcoma

NCT07725380

Clinical

Trials by Indication[1]

Melanoma1 trial

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT04133948·44 enrolled

Intestinal Cancer1 trial

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT03812796·75 enrolled

Sarcoma1 trial

Open-Label, Cohort-Sequential Dose-Escalation and Dose-Confirmation Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of Domatinostat in Combination With Sirolimus in Adolescents and Adults With Relapsed, Refractory Sarcoma and Osteosarcoma

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Preclinical·NCT07725380·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Domatinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Domatinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Domatinostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Royal Marsden NHS Foundation Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRoyal Marsden NHS Foundation Trust

Domatinostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Melanoma1 trial

Intestinal Cancer1 trial

Sarcoma1 trial

References

Drug Info

Quick Facts

Related News